Suppression of tumorigenicity by MicroRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 10, 2013, Pages 1697-1707

  Qiu, Shuwei ^a   Huang, Daquan ^a   Yin, Deling ^b   Li, Fangcheng ^a   Li, Xiangping ^a   Kung, Hsiang fu ^c   Peng, Ying ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b East Tennessee State University   (United States)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma multiforme microRNA 138 EZH2 CDK6 tumorigenicity TCGA

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; MICRORNA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR EZH2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING;

GLIOBLASTOMA MULTIFORME/MICRORNA-138/EZH2/CDK6/TUMORIGENICITY/TCGA;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; E2F1 TRANSCRIPTION FACTOR; GLIOBLASTOMA; HUMANS; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 2; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION;

EID: 84879567465     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.05.015     Document Type: Article

References (54)

1. Huang P.H., Xu A.M., White F.M. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2009, 2(87).
2. Preusser M., et al. Current concepts and management of glioblastoma. Ann. Neurol. 2011, 70(1):9-21.
3. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
4. Inui M., Martello G., Piccolo S. MicroRNA control of signal transduction. Nat. Rev. Mol. Cell Biol. 2010, 11(4):252-263.
5. Asadi-Moghaddam K., Chiocca E.A., Lawler S.E. Potential role of miRNAs and their inhibitors in glioma treatment. Expert. Rev. Anticancer. Ther. 2010, 10(11):1753-1762.
6. Bader A.G., Brown D., Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70(18):7027-7030.
7. Kefas B., et al. MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68(10):3566-3572.
8. Webster R.J., et al. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J. Biol. Chem. 2009, 284(9):5731-5741.
9. Kefas B., et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J. Neurosci. 2009, 29(48):15161-15168.
10. Kefas B., et al. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010, 12(11):1102-1112.
11. Gabriely G., et al. Human glioma growth is controlled by microRNA-10b. Cancer Res. 2011, 71(10):3563-3572.
12. Crea F., Hurt E.M., Farrar W.L. Clinical significance of polycomb gene expression in brain tumors. Mol. Cancer 2010, 9:265.
13. Suva M.L., et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009, 69(24):9211-9218.
14. Orzan F., et al. Enhancer of zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol. Appl. Neurobiol. 2011, 37(4):381-394.
15. Margueron R., Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011, 469(7330):343-349.
16. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 2008, 647(1-2):21-29.
17. Tonini T., et al. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J. Cell. Physiol. 2008, 214(2):295-300.
18. Michaud K., et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010, 70(8):3228-3238.
19. Chen H.Z., Tsai S.Y., Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 2009, 9(11):785-797.
20. Alonso M.M., et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J. Natl Cancer Inst. 2005, 97(21):1589-1600.
21. Bracken A.P., et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22(20):5323-5335.
22. Polager S., Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol. 2008, 18(11):528-535.
23. Camara-Quintana J.Q., Nitta R.T., Li G. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurg. Clin. N. Am. 2012, 23(2):237-246. (viii).
24. Wang Y., et al. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol. Cancer Res. 2011, 9(8):1100-1111.
25. Rivetti di Val Cervo P., et al. p63-microRNA feedback in keratinocyte senescence. Proc. Natl. Acad. Sci. U. S. A. 2011, 109(4):1133-1138.
26. Siegel G., et al. A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat. Cell Biol. 2009, 11(6):705-716.
27. Morton S.U., et al. microRNA-138 modulates cardiac patterning during embryonic development. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(46):17830-17835.
28. Kisliouk T., Yosefi S., Meiri N. MiR-138 inhibits EZH2 methyltransferase expression and methylation of histone H3 at lysine 27, and affects thermotolerance acquisition. Eur. J. Neurosci. 2011, 33(2):224-235.
29. Jiang L., et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int. J. Cancer 2008, 127(3):505-512.
30. Liu X., et al. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem. J. 2011, 440(1):23-31.
31. Song T., et al. MiR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev 2011, 12(5):1307-1311.
32. Wang W., et al. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 2012, 33(5):1113-1120.
33. Zheng F., et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012, 61(2):278-289.
34. Wang Q., et al. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp. Lung Res. 2011, 37(7):427-434.
35. Seike M., et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(29):12085-12090.
36. Mitomo S., et al. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci. 2008, 99(2):280-286.
37. Zhao X., et al. miR-138 might reverse multidrug resistance of leukemia cells. Leuk. Res. 2010, 34(8):1078-1082.
38. Li D., et al. Grade-specific expression profiles of miRNAs/mRNAs and docking study in human grade I-III astrocytomas. Omics 2011, 15(10):673-682.
39. Chan X.H., et al. Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas. Cell Rep. 2012, 2(3):591-602.
40. Brescia P., Richichi C., Pelicci G. Current strategies for identification of glioma stem cells: adequate or unsatisfactory?. J. Oncol. 2012, 2012:376894.
41. Jiang L., et al. miR-182 as a prognostic marker for glioma progression and patient survival. Am. J. Pathol. 2010, 177(1):29-38.
42. Tucker-Burden C., et al. Lectins identify glycan biomarkers on glioblastoma-derived cancer stem cells. Stem Cells Dev. 2012, 21(13):2374-2386.
43. Chang C.J., Hung M.C. The role of EZH2 in tumour progression. Br. J. Cancer 2011, 106(2):243-247.
44. Smits M., et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 2010, 1(8):710-720.
45. Lu J., et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011, 71(1):225-233.
46. Wiedemeyer W.R., et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(25):11501-11506.
47. Silber J., et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008, 6:14.
48. Pierson J., et al. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J. Neurooncol. 2008, 90(1):1-7.
49. Berezowska S., Schlegel J. Targeting ErbB receptors in high-grade glioma. Curr. Pharm. Des. 2011, 17(23):2468-2487.
50. Atlas C. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068.
51. Wu Z.L., et al. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ. 2010, 17(5):801-810.
52. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
53. Cha T.L., et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005, 310(5746):306-310.
54. Chen S., et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol. 2010, 12(11):1108-1114.